AI-Powered, Next-Generation Sequencing Blood-Based Assay Evaluated for Detection of Post-HCT Relapse in AML and MDS - Summary - MDSpire
From the Journals

AI-Powered, Next-Generation Sequencing Blood-Based Assay Evaluated for Detection of Post-HCT Relapse in AML and MDS

Monitoring for relapse with an artificial intelligence (AI)-powered peripheral blood-based tool called AlloHeme demonstrated greater sensitivity in predicting relapse after hematopoietic cell transpla...

  • By

  • Lisa Astor

  • May 8, 2026

  • 8 min

Share

The ACROBAT study revealed that the AI-powered AlloHeme tool significantly improves relapse prediction in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) following hematopoietic cell transplantation (HCT). Conducted over two years, the study demonstrated AlloHeme's superior sensitivity in detecting relapse compared to standard testing methods. The tool achieved 85% sensitivity and detected relapse a median of 41 days before clinical signs, potentially enhancing early intervention strategies.

Original Source(s)

AI-Powered, Next-Generation Sequencing Blood-Based Assay Evaluated for Detection of Post-HCT Relapse in AML and MDS

  • by Lisa Astor

  • May 8, 2026

Related Content

Acupuncture for Nocturia in Survivors of Prostate Cancer

Guest Editor’s Note: Nocturia, waking up from sleep more than once to urinate, is prevalent in survivors of prostate cancer and is associated with a diminished quality of life and a higher mortality t...

Gerald Hsu, MD, PhD, Named Editor-in-Chief of the ASCO Educational Book

ASCO is pleased to announce the appointment of Gerald Hsu, MD, PhD, as the new Editor-in-Chief of the ASCO Educational Book.    

  • by ASCO

  • May 8, 2026

  • 2 min
National Academy of Medicine Recognizes 100 Newly Elected Members

Election to the National Academy of Medicine recognizes individuals who have demonstrated outstanding professional achievement and commitment to service.